Administration of G–CSF plus dexamethasone producesgreater granulocyte concentrate yields while causing nomore donor toxicity than G–CSF alone

BACKGROUND: G–CSF with or without dexamethasone is becoming the standard agent for mobilizing granulocytes for transfusion. The purpose of this study was to determine if the toxicities of G–CSF with or without dexamethasone are offset by greater collection yields and to define the minimum interval that should separate sequential collections.

[1]  W. Liles,et al.  Combined administration of G–CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing , 2000, Transfusion.

[2]  M. Boeckh,et al.  Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. , 2000, Blood.

[3]  R. Vij,et al.  Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. , 2000, Blood.

[4]  D. Stroncek,et al.  Effects of granulocyte–colony‐stimulating factor on potential normal granulocyte donors , 1999, Transfusion.

[5]  Smith,et al.  Collection of two peripheral blood stem cell concentrates from healthy donors , 1999, Transfusion medicine.

[6]  H. Kantarjian,et al.  Evaluation and comparison of three mobilization methods for the collection of granulocytes , 1998, Transfusion.

[7]  W. Liles,et al.  Neutrophil transfusions: kinetics and functions of neutrophils mobilized with granulocyte‐colony‐stimulating factor and dexamethasone , 1998, Transfusion.

[8]  W. Velasquez,et al.  Transfusions of granulocyte‐colony‐stimulating factor‐mobilized granulocyte components to allogeneic transplant recipients: analysis of kinetics and factors determining posttransfusion neutrophil and platelet counts , 1997, Transfusion.

[9]  D. Adkins,et al.  Indium-labeled white blood cells apheresed from donors receiving G-CSF localize to sites of inflammation when infused into allogeneic bone marrow transplant recipients , 1997, Bone Marrow Transplantation.

[10]  W. Liles,et al.  A comparative trial of granulocyte‐colony‐stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers , 1997, Transfusion.

[11]  P. Anderlini,et al.  Transient neutropenia in normal donors after G‐CSF mobilization and stem cell apheresis , 1996, British journal of haematology.

[12]  D. Stroncek,et al.  Treatment of normal individuals with granulocyte‐colony‐stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells , 1996, Transfusion.

[13]  D. Stroncek,et al.  Changes in blood counts after the administration of granulocyte‐colony‐ stimulating factor and the collection of peripheral blood stem cells from healthy donors , 1996, Transfusion.

[14]  R. Champlin,et al.  Clinical toxicity and laboratory effects of granulocyte‐colony‐ stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures , 1996, Transfusion.

[15]  E. Anaissie,et al.  Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection , 1995, Journal of clinical apheresis.

[16]  R. Strauss.  Clinical perspectives of granulocyte transfusions: Efficacy to date , 1995, Journal of clinical apheresis.

[17]  R. Strauss.  Therapeutic granulocyte transfusions in 1993. , 1993, Blood.

[18]  R Storb,et al.  The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. , 1993, Blood.

[19]  Standards for blood banks and transfusion services. , 1977, QRB. Quality review bulletin.